NeuroSense Therapeutics has received approval from the Nasdaq Hearings Panel to maintain its listing, conditional upon filing public disclosure by December 18, 2024. The company must demonstrate compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million and provide income projections.The compliance issue arose after a June 21, 2024 notice from Nasdaq indicating the company's failure to meet the minimum stockholders' equity requirement. Following a hearing on August 1, 2024, where NeuroSense presented its compliance plan, the Panel initially granted an extension until October 31, 2024. The current extension represents additional time for the company to achieve compliance.The continuation of NeuroSense's Nasdaq listing remains subject to the Panel's ongoing review and the company's ability to meet the specified conditions. This development is crucial for NeuroSense as it continues its clinical trials and development of PrimeC for ALS treatment.

NeuroSense Therapeutics has received approval from the Nasdaq Hearings Panel to maintain its listing, conditional upon filing public disclosure by December 18, 2024. The company must demonstrate compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million and provide income projections.The compliance issue arose after a June 21, 2024 notice from Nasdaq indicating the company's failure to meet the minimum stockholders' equity requirement. Following a hearing on August 1, 2024, where NeuroSense presented its compliance plan, the Panel initially granted an extension until October 31, 2024. The current extension represents additional time for the company to achieve compliance.The continuation of NeuroSense's Nasdaq listing remains subject to the Panel's ongoing review and the company's ability to meet the specified conditions. This development is crucial for NeuroSense as it continues its clinical trials and development of PrimeC for ALS treatment.